| Abstrakt: |
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1-3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM-2 Encore Abstract - previously submitted to EHA 2023 The research was funded by: Regeneron Pharmaceuticals, Inc. Keywords: immunotherapy, indolent non-Hodgkin lymphoma B Conflicts of interests pertinent to the abstract b B S. Novelli b Consultant or advisory role: Mundipharma Research funding: Novartis B S. Luminari b Consultant or advisory role: Roche, Kite, BMS, Janssen Other remuneration: Speakers Bureau fees for BMS and Janssen B M. Taszner b Consultant or advisory role: Roche, Takeda Honoraria: Roche, Takeda, Novartis, Servier Educational grants: Roche B S. Le Gouill b Consultant or advisory role: Novartis, Kite/Gilead, Janssen Honoraria: Novartis, Kite/Gilead, Janssen Educational grants: Novartis, Kite/Gilead, Janssen B R. Champion b Other remuneration: Speaker bureau fees from AbbVie and BMS B E. Bachy b Consultant or advisory role: Roche, Gilead, ADC Therapeutics, Takeda, Novartis, Incyte Honoraria: Kite, Gilead, Novartis, Roche, Incyte, Miltenyi Biotech, Takeda, Sanofi Research funding: Amgen, BMS B S. Guidez b Honoraria: Gilead/Kite, Takeda, Incyte, AstraZeneca B A. Alonso b Consultant or advisory role: Abbvie, Janssen, Incyte, GlaxoSmithKline Honoraria: Abbvie, Janssen, Incyte, GlaxoSmithKline. B Introduction: b Odronextamab is a CD20 × CD3 bispecific antibody (Ab). [Extracted from the article] |
Plný text